上海医药枸橼酸托法替布缓释片获批生产

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Tocilizumab Sustained-Release Tablets, which are indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1] Company Summary - The approved drug, Tocilizumab Sustained-Release Tablets, was originally developed by Pfizer and was launched in the United States in 2016 [1] Industry Summary - The approval of Tocilizumab Sustained-Release Tablets marks a significant development in the pharmaceutical industry, particularly in the treatment options available for autoimmune diseases [1]